OncoSil Medical (ASX:OSL) shares jump 14% on G-BA approval

March 28, 2022 01:30 PM AEDT | By Aditi Sarkar

OncoSil Medical (ASX:OSL) shares jump 14% on G-BA approval — Image source: © Designer491 | Megapixl.com

G-BA approves trial in Germany

Today, the company announced to have received approval from the Federal Joint Committee (G-BA) for conducting the trial to assess the OncoSil device compared with chemotherapy in the treatment of Locally Advanced Pancreatic Cancer (LAPC).

The OncoSil™ device has a Breakthrough Device designation in the US, UK and Europe with a CE mark in Europe and the UK.

Potential benefits from the trial

The comparative trial will represent remarkable opportunity for OncoSil to improve the current body of evidence.
Successful results from the G-BA clinical trial are expected to aid in securing public funding to treat patients in Germany with unresectable locally advanced pancreatic cancer.
OncoSil will also get additional device sales revenues for the provision of OncoSil™ during the study.

The commencement and funding of a clinical trial follow the receipt of a “Positive Status 1” classification under the innovation funding (NUB) program. The G-BA decision and the classification under the NUB program are expected to remarkably boost the profile of the OncoSil™ device with Key Opinion Leaders and stakeholders in the German market and throughout the EU and the UK.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.